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Neurodegenerative diseases are hereditary or sporadic conditions that result in the progressive loss of the structure and function
of neurons as well as neuronal death. Although a range of diseases lie under this umbrella term, Alzheimer’s disease (AD)
and Parkinson’s disease (PD) are the most common neurodegenerative diseases that affect a large population around the
globe. Alzheimer’s disease is characterized by the abnormal accumulation of extracellular amyloid-𝛽 plaques and intraneuronal
neurofibrillary tangles in brain regions andmanifests as a type of dementia in aged individuals that results inmemory loss, multiple
cognitive abnormalities, and intellectual disabilities that interfere with quality of life. Since the discovery of AD, a wealth of new
information has emerged that delineates the causes, mechanisms of disease, and potential therapeutic agents, but an effective
remedy to cure the diseases has not been identified yet.This could be because of the complexity of the disease process, as it involves
various contributing factors that include environmental factors and genetic predispositions. This review summarizes the current
understanding on neurodegenerative mechanisms that lead to the emergence of the pathology of AD.
1. Introduction
Alzheimer’s disease is characterized by the pathological
accumulation of amyloid-𝛽 (A𝛽) peptides and tau protein,
leading to the formation of neurofibrillary tangles and the
loss of neuronal cells. Amyloid beta, a 39–43-amino acid
residue peptide, is found in the healthy human brain and
is considered to have a normal physiological role. It exists
as A𝛽 fibrils because of cleavage from a larger amyloid
precursor protein [1]. In AD, the accumulation of amyloid
fibrils as amyloid plaques or senile plaques in extracellular
region of brain cells is closely linked to the loss of synapses,
synaptic dysfunction, inflammatory responses, and neuronal
loss. On the other hand, tau protein or T proteins are found
abundantly in definite spatial patterns in the entorhinal
cortex followed by hippocampal and cortical areas of the
central nervous system and plays a vital role in stabiliz-
ing microtubule. In AD pathology, the tau protein under-
goes intense hyperphosphorylation, leading to the clumping
of tau protein, which forms intracellular neurofibrillary
tangles (NFT). The intracellular formation of NFT leads
to microtubule disassembly, dendritic spinal collapse, and
the degeneration of axons. The pathological aggregation of
intracellular NFT and extracellular senile plaques precede the
initial signs of cognitive impairment in mild AD patients by
at least 10–20 years. Mild signs of AD include memory loss,
mood changes, nervousness, difficulty in handling money,
and poor judgement. However, in late-stage AD, patients will
need full time, around the clock assistance as more severe
cognitive alterations, such as a loss in the ability to respond to
the environment, confusion, restlessness, and difficulty with
language and thoughts, as well as difficulty in the control of
movement, will be experienced by patients [2].
2. Common Neurodegenerative
Mechanisms in AD
2.1. Mitochondrial Dysfunction and ROS Production. Neu-
rons in the human brain have tremendous oxygen consump-
tion and metabolic rates. For this reason, neurons rely on
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mitochondria that are found in abundance in brain tissues
for the production of energy by oxidative phosphoryla-
tion. Mitochondria are the central sites of ROS, as natural
byproducts of the oxidative phosphorylation cascade, and
excessive production of ROS is usually offset by the normal
homeostasis function of mitochondria.
A𝛽 appears as a solitary molecule but tends to form
small clusters that are soluble and able to travel freely in
the brain and eventually forms plaques that are hallmarks
of AD. Recent studies have highlighted the effect of A𝛽
on mitochondrial respiratory function, including mitochon-
drial complexes I–IV activities and mitochondrial oxygen
consumption [3]. Chen and Yan have shown that A𝛽 can
penetrate the mitochondrial membrane and interact with
internal mitochondrial protein abnormalities and decrease
the activity of the mitochondrial electron transfer chain, the
citric acid cycle, and the generation of ROS [4]. Moreover,
Cha et al. have demonstrated that exposure of the hippocam-
pal cell line ofmice (HT22 cells) to exogenousA𝛽
1–42 induced
identical morphological alterations as those observed in
A𝛽PP/PS1 double transgenic mice. A𝛽
1–42 accumulation in
mitochondria induces cellular toxicity and leads to cellu-
lar death [5]. Mitochondrial associated amyloid precursor
protein (APP) forms a complex with the translocase of the
outermitochondrial membrane 40 (TOM40) import channel
and the translocase of the inner mitochondrial membrane
23 (TIM23) import channel and causes the inhibition of
nuclear-encoded cytochrome c oxidase subunits IV and
Vb proteins. Following this event, cytochrome c oxidase
activity is decreased and the generation of hydrogen peroxide
is increased in mitochondria. This finding correlated with
a higher level of regional dissemination of mitochondrial
APP in AD-vulnerable areas, including the frontal cortex,
hippocampus, and amygdala [6]. Studies have also shown
that mitochondrial accumulated A𝛽 induced mitochondrial
damage and neuronal death. Proteomic studies that used
triple transgenic mice (pR5/APP/PS2) that carried both
plaques and tangles demonstrated an enormous downreg-
ulation of proteins related to complexes I and IV of the
oxidative phosphorylation system [7]. Emerging evidence
supports that an interaction between the amino terminal
(NH(2))-derived tau fragment of the human tau40 isoform
and APP is closely associated with mitochondrial adenine
nucleotide translocator-1 (ANT-1) and cyclophilin D. The
two peptides inhibit the ANT-1 dependent adenosine diphos-
phate adenosine triphosphate (ADP/ATP) exchange and
exacerbate mitochondrial dysfunction and synaptic deteri-
oration in AD pathology [8]. However, the mechanisms
related to mitochondrial impairment that lead to AD remain
unclear.
2.2. Protein Oxidation. There is much accumulated evidence
that ROS may be central to the pathogenesis of neurode-
generation in AD. The incessant build-up of ROS and RNS
(reactive nitrogen species) leads to protein oxidation and lipid
peroxidation. Furthermore, the human brain is composed
of high levels of unsaturated lipid content and exhibits high
oxygen utilization, an increased level of metal ions, and a
comparatively poor antioxidant system, which makes the
brain extremely vulnerable to protein oxidation and lipid
peroxidation.
Protein oxidation in cell is reflected by the increased
levels of protein carbonyls and 3-nitrotyrosine (3-NT). Pro-
tein carbonyls can be generated by the reaction of the
superoxide anion, which leads to the fragmentation of the
protein backbone. In addition, protein carbonyls may also
be generated by hydrogen atom abstraction and the specific
attack of ROS on several amino acid side chains, such as
lysine, arginine, and proline. Studies have also demonstrated
that the ROS attack on protein structure may result in the
formation of Michael adducts between lysine, histidine, and
cystine residues and the glycation/glycoxidation of lysine
amino groups, which forms advance glycation end products
(AGEs) [9, 10]. However, protein carbonyls are considered a
disease marker but the source of formation by either direct
protein oxidation or the addition of previously oxidised
molecules cannot be differentiated. As protein carbonylation
and modification cannot be repaired, these altered com-
pounds must be eliminated from the intracellular compart-
ments by selective proteolysis. Bota et al. have reported that
the improper clearance of modified proteins and aggregates
may contribute to a range of human pathologies [11]. Sub-
stantial evidence demonstrated that the protein carbonyl
level was increased by 42% and 37% in the AD hippocam-
pus and inferior parietal lobule, respectively [12]. More
recently, researchers have identified other modified proteins,
such as 𝛼-enolase, ubiquitin carboxyl terminal hydrolase L-
1 (UCHL-1), dihydropyrimidinase-related protein 2, heat-
shock cognate 71, creatine kinase BB, and peptidyl prolyl-
cis,trans isomerase 1 (Pin1), in different brain regions of AD
patients by using a redox proteomic approach. Importantly,
recent lines of evidence have indicated that some biochemical
alterations exist in proteins that play a crucial role directly
or indirectly in mitochondrial energy metabolism, such as
creatine kinase, triosephosphate isomerase, glyceraldehyde 3-
phosphate dehydrogenase, phosphoglycerate mutase 1, and
𝛼-ATPase. The oxidation of these vital enzymes caused
a decrease in ATP generation to maintain the normal
metabolism and functions of neuronal cells, which resulted
in the perturbation of ion pump and potential gradients.
In addition, ATP deprivation in brain cells can cause an
abnormal phosphorylation of tau protein, which can progress
to AD disease onset [13].
2.3. Lipid Peroxidation. Lipid peroxidation refers to oxidative
degradation of lipid molecules. It is a chain reaction whereby
an H atom is abstracted from lipids in cell membranes by free
radical species, resulting in cell membrane damage.The brain
is considered vulnerable to lipid peroxidation due to its high
oxygen consumption, high level of redox metal ions, reduced
antioxidant defence mechanism, and high level of polyun-
saturated fatty acids (PUFAs). The toxic reaction between
free radicals and phospholipid-bound arachidonic acid in
cell membrane produces free 4-hydroxy-2-trans-nonenal
(HNE), acrolein, neuroprostanes, and isoprostanes [14]. The
aldehydic product of lipid peroxidation HNE is highly toxic
and can form covalent bonds with proteins through Michael
adduction to amino acid cysteines, lysines, and histidines.
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A recent study reported elevated levels of HNE-histidine
Michael adducts in the AD hippocampus and the covalent
modification of the histidine side chain of A𝛽 results in an
increased aggregation of this tau protein [15].The aggregation
of A𝛽 in mitochondrial membranes causes alterations and
increased permeability in the membrane, which leads to the
leakage of cytochrome c and the functional abnormality of
the electron transport chain, which culminates in cellular
apoptosis. Moreover, Tamagno et al. demonstrated in an
in vivo study that increased lipid peroxidation results in
increased A𝛽 production via the BACE 1 expression pathway
[16]. Importantly, lipid peroxidation and A𝛽 generation in
neuronal cells are capable of inducing JNK pathways, leading
to programmed neuronal death. As an aldehydic product
of lipid peroxidation, HNE is a highly lethal compound
that impairs the coupling of metabotropic glutamate and
muscarinic cholinergic receptors to phospholipaseC-coupled
GTP-linked proteins in cultured rat cerebrocortical neurons
[17]. In addition, HNE hinders glucose transport in cultured
hippocampal neurons and inhibits glutamate transport in
cortical astrocytes [18]. The lipid peroxidation of arachi-
donic acid forms prostaglandin-like compounds known as
isoprostanes. Montine et al. indicated that isoprostane lev-
els are selectively elevated in brain tissues from patients
with advanced AD, which also exhibit the deposition of
A𝛽, neurofibrillary tangle formation, and neurodegeneration
[19].
2.4. Nitrosative Stress. Nitrosative stress is a condition
whereby RNS generation is not counterbalanced by an
array of defence mechanisms and causes damage to the
intracellular components of cells. Nitric oxide (NO), the
major contributor of RNS, functions as signalling molecule
in regulating neural development, neurotransmitter release,
and synaptic plasticity [20]. NO is produced by three types
of nitric oxide synthase enzymes (NOS), namely, inducible
nitric oxide synthase (iNOS), endothelial NOS (eNOS), and
neuronal NOS (nNOS). RNS arise from a combination of the
superoxide radical (∙O−) and NO that forms a nitric oxide
radical (∙NO−), a peroxynitrite anion (ONOO−), nitrogen
dioxide (NO
2
−), and Dinitrogen trioxide (N
2
O
3
) [21].
Nitrosative stress has been implicated in marked cogni-
tive impairment that is associated with synaptic dysfunction
and glial activation. A substantial body of evidence has
indicated that A𝛽
1–40 in an AD mice model promoted the
activation of iNOS and tumour necrosis factor-𝛼 (TNF-
𝛼) that subsequently led to the activation of c-Jun-NH2-
terminal kinase (JNK) andNuclear Factor-KB and significant
learning and memory impairment [22]. Emerging studies
have suggested that the dynamics ofmitochondria fission and
fusion are essential in maintaining mitochondrial function
as well as maximizing bioenergetic capacity. However, nitric
oxide produced in response to A𝛽 in AD has been found
to induce mitochondrial fission thorough the S-nitrosylation
of dynamin-related protein 1 (SNO-Drp1), causing synap-
tic impairment and neuronal damage [23]. Moreover, A𝛽
induced dendritic spine loss in AD has been found to be
mediated by the activation of Cdk5 by the S-nitrosylation
of thiol groups of cysteine residues to form SNO-Cdk5.
Increased SNO-Cdk5 activity has been linked to the patho-
genesis of AD, as increased levels of SNO-Cdk5were detected
in postmortem AD brain samples but not in normal samples
[24]. Along this line, numerous studies have been carried
out to identify the different types of protein S-nitrosylation
in the progression of AD. Zahid et al. have demonstrated
that 45 endogenous nitrocysteines primarily involved in
neuronal metabolism, signalling pathways, apoptosis, and
redox regulation were identified from the hippocampus,
substantia nigra, and cortex of AD patients. Furthermore,
extensive neuronal atrophy in the AD brain with increased
protein S-nitrosylation and a significant number of cysteine
modification sites facilitates the understanding of the involve-
ment of S-nitrosylation in nitrosative stress induced AD
pathology [24, 25].
2.5. Protein Aggregation. AD is the most prevalent neurode-
generative disease that is characterized by protein aggrega-
tion and inclusion body formation. Alzheimer’s disease is
identified by twomain pathological lesions: the deposition of
neuritic plaques that consist of amyloid-𝛽 and intraneuronal
neurofibrillary tangles that consist of hyperphosphorylated
tau protein.
2.6. Amyloidopathy. The deposition of amyloid beta (A𝛽)
peptide, the main component of senile plaques in neuronal
cells, is known as “amyloidopathy.” It is becoming clear that
the extracellular aggregation of A𝛽 plaques is closely associ-
ated with widespread neuronal atrophy and the concomitant
damage of synapses in different brain regions that results in
gradual neuronal death and memory loss. An initial study
by Hardy et al. has documented that several environmental
factors, including oxidative stress, drug and brain injury, and
genetic variants, can contribute to the pathogenesis of AD.
The amyloid cascade hypothesis, originally presented by
Hardy and Higgins in 1992, is the most accepted and well
understood mechanism of deposition of the amyloid beta
protein in Alzheimer’s pathology. Amyloid precursor protein
(APP) is a large transmembrane protein that produces A𝛽
that consists of either 40 or 42 amino acids. A𝛽
40
is a
commonly found protein molecule whereby A𝛽
42
is highly
toxic to neuronal cells. In physiological states, the membrane
glycoprotein APP plays a crucial role in synapse formation
and neuronal activity and transmission via two proteolytic
pathways: “nonamyloidogenic” and “amyloidogenic” path-
ways [26]. In the “nonamyloidogenic” pathway, soluble APP𝛼
is released to the extracellular compartment through APP
cleavage that involves 𝛼- and 𝛾-secretases. On the other hand,
the “amyloidogenic” pathway is triggered by 𝛽-secretase 1 (𝛽-
site amyloid precursor protein cleaving enzyme 1, BACE-1)
mediated cleavage that produces soluble extracellular APP𝛽,
which is subsequently cleaved by a 𝛾-secretase complex that
releases A𝛽 into the extracellular space [27]. Subsequently,
A𝛽 is transported and degraded by the ApoE2 and ApoE3
isoform and cleared completely through the blood brain
barrier together with insulin degrading enzyme (IDE) or
with the neprilysin degradation pathway (NDP). However,
the binding of A𝛽 to the ApoE4 isoform leads largely to A𝛽
aggregation in the extracellular region of the central nervous
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system. In normal conditions, during A𝛽 generation, there
is a feedback mechanism that releases the APP intracellular
C-terminal domain and increases the level of neprilysin,
which promotes A𝛽 turnover. Perturbation of the physio-
logical pathway may occur in the event of mutations and
changes in the expression of APP, BACE-1, IDE, Apo-E, and
neprilysin lead to the progressive accumulation of A𝛽 and the
manifestation of AD [28].
2.7. Tauopathies. Tauopathies are diseases associated with
the intracellular pathological aggregation of tau protein
in neurofibrillary tangles, which is observed in almost 26
neurodegenerative diseases, including Alzheimer’s disease,
progressive supranuclear palsy (PSP), Dementia Pugilistica,
and Pick’s disease. In AD, the paired helical filament type
of tau aggregates and forms tangles in neuronal cells, which
leads to neurodegeneration and leaves the tau aggregates
appearing as neurotoxic “ghost-tangles” [29]. It has been
widely understood that tau is a microtubule binding protein
that is found largely in neurons, specifically in axons and
dendrites. Tauprotein functions in themaintenance ofmicro-
tubule stabilization, cellular morphology, and the axonal
movement of organelles and vesicles [29]. The expression of
six isoforms of the tau protein in human neurons is regulated
by the microtubule-associated protein tau (MAPT) gene in
chromosome 17. The six isoforms are 4R2N, 4R1N, 3R2N,
4R0N, 3R1N, and 3R0N, and they are produced as a result
of alternative mRNA splicing of the MAPT gene; the shortest
form, the 3R0N isoform, is expressed predominantly in the
foetal brain. These 6 isoforms differ from one another by
the inclusion and exclusion of one or two inserts (29 or 58
amino acids) in N-terminal sequences and by the presence
or absence of a long microtubule binding repeat domain in
the C-terminal half [30]. The loss of functional tau due to
hyperphosphorylation state of paired helical filament (PHF)
of all 6 isoforms of tau proteins is the pathological hallmark
of AD which leads to disruption in microtubule assembly,
decreased axonal transport, and neurodegeneration in areas
such as frontotemporal lobe of humanbrain. Ko¨pke et al. have
demonstrated that cytosolic hyperphosphorylated tau from
AD patients contains 5 to 9mols of phosphate per mol of tau
protein in comparison to normal tau, which only contains
two to three mols of phosphate per mol of tau protein [31].
Emerging studies have found a correlation between a
decrease in brain insulin signalling and the level of hyper-
phosphorylation of tau protein in AD. These data were
further bolstered by epidemiological studies that showed
that diabetic patients with a high level of glycated proteins
have a higher risk of developing AD. Hence, the increased
glycosylation of tau protein results in tau protein that is
more susceptible to phosphorylation by cAMP-dependent
protein kinase (PKA), glycogen synthase kinase-3𝛽 (GSK-
3𝛽), and cyclin-dependent protein kinase 5 (cdk5), but is also
more sensitive to the downregulation of dephosphorylation
by protein phosphatase 2A (PP-2A). The activity of PP-2A
is markedly reduced in AD, which could be one of the
contributing factors of the abnormal hyperphosphorylation
of the tau protein. These toxic proteins cause the inhibition
and breakdown of microtubule structures in neurons and
further cause impairment in axonal transport, leading to a
“domino” cascade of events that result in dementia [32].
A plethora of scientific evidence has clearly indicated that
an increased generation of reactive oxygen species (ROS)
that is not counterbalanced by an internal defence mech-
anism results in oxidative stress and the manifestation of
neurodegeneration diseases. Interestingly, recent studies have
demonstrated a crosslink between mitochondrial oxidative
stress and the hyperphosphorylation of tau protein. Studies
carried out on null mice that lack the superoxide dismutase
2 (SOD2) gene showed that treatment with a catalytic low
dose of antioxidant resulted in the elevation of tau phos-
phorylation specifically at the Ser-396 amino acid sequence.
However, tau phosphorylation was halted with the admin-
istration of a high dose of antioxidant supplement, which
indicates that an efficient internal antioxidant defence system
prevents tau hyperphosphorylation and the manifestation
of AD neuropathology [33]. These in vivo findings are also
supported by in vitro studies whereby phosphorylated tauwas
markedly increased via the inhibition glutathione synthesis in
M17 neuroblastoma cells [34].
2.8. DNA Damage. Deoxyribonucleic acid (DNA) is located
in the nucleus and mitochondria of living cells. The mater-
nally inherited human mitochondrial DNA (mtDNA) is
circular in shape with a size of approximately 16.5 kb and
encodes 13 polypeptides, 22 tRNAs, and 2 rRNAs. These
proteins play crucial roles in orchestrating the oxidative phos-
phorylation pathway through the electron transport chain to
generate ATP. Several lines of evidence have suggested that
nuclear and mitochondrial DNA are subjected to genotoxic
assault by ROS produced as a byproduct of the oxidative
phosphorylation cascade and exposure to environmental
toxins and radiation. As mtDNA is located in close proximity
to the oxidative phosphorylation cascade, studies have sug-
gested that mtDNA is more susceptible to genotoxic assault
than nDNA. However, more studies should be carried out to
understand the actual reason for the increased susceptibility
of mitochondrial DNA damage in comparison to nDNA.
Therefore, to overcome DNA damage, mammalian mito-
chondria are equipped with inimitable DNA repair pathways
that respond to oxidative DNAdamage.Whether these repair
proteins are of nuclear origin or preexist in mitochondria at
the point of oxidative DNA damage is not clearly understood.
The damaged DNA is subjected to DNA repair pathways that
include base excision repair (BER), direct reversal, mismatch
repair, translesion synthesis, and double-strand break repair
[35].
Tau protein plays a key role in safeguarding the integrity
of neuronal genomic DNA from ROS and oxidative stress in
addition to its role in microtubule dynamics. An alteration in
tau protein may result in a loss of nucleic acid safeguarding
functions and increase the susceptibility to ROS induced
oxidative damage in genomic DNA and nuclear RNA in
hippocampal neurons in AD patients. ROS have been shown
to cause DNA strand breaks and to contribute to downstream
events in the disease mechanism of AD. This correlation
was suggested byMullaart and colleagues; they demonstrated
a 2-fold increase in DNA damage in AD brain neurons
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Figure 1: Activated Nuclear Factor 2 (Nrf2) by oxidative stress enters nucleus and escalates the transcription of ARE-containing genes.These
genes cause the expression of antioxidant enzymes, that is, SOD (superoxide dismutase), Glut (glutathione), GPx (glutathione peroxidase),
CAT (catalase), and GST (reduced glutathione). Subsequently, these enzymes will catalyse the detoxification of ROS and protect neuronal
cells from damage. Glycogen synthase kinase-3𝛽 participates in phosphorylation of tau protein and induce accumulation of neurofibrillary
tangles (NFT) that inhibits Nrf2. Besides inhibiting NRf2 activity, alpha-synuclein and NFT stimulate oxidative stress via ROS production.
and suggested that this could be the earliest detectable
pathological changes in the progression from normal to AD
brain [36]. Along these lines, an increase in damaged DNA
bases, namely, 8-hydroxyadenine, 8-hydroxyguanine, Fapy-
guanine, 5-hydroxyuracil, and Fapy-adenine, was identified
in the parietal, temporal, occipital, and superior gyrus and
in the hippocampus region in patients with AD. The most
protuberant DNA marker discovered in most biological
samples, such as blood cells, urine, and brain specimens, is
8-hydroxyguanine (8-OHG). Mecocci and colleagues have
demonstrated a significant 3-fold increase in the level of
the DNA marker 8-OHG in the parietal cortex region in
AD patients compared to normal individuals, specifically
in mitochondrial DNA (mtDNA) compared to nuclear
DNA [37]. Essentially, in normal cells the 8-OHG oxidative
adduct is recognized and excised by a base repair pro-
tein, 8-oxoguanine-DNA glycosylase (OGG1) [38]. OGG1
is a bifunctional enzyme with both DNA glycosylase and
apurinic/apyrimidinic lyase activities. A substantial body of
evidence has identified two mutations of OGG1 that are
single-nucleotide polymorphisms as a result of amino acid
substitutions A53T and A288V. In 2007, these A53T and
A288V polymorphic OGG1 proteins were detected in brain
tissue from late-stage AD patients but were absent in a
control group [39]. Tissues with A53T polymorphic OGG1
that were found to have decreased catalytic activity due to a
reduced ability to bind DNA substrates and A288V protein
demonstrated decreased lyase activity, leaving the DNAmore
susceptible to oxidative damage [40].
2.9. Depletion of Endogenous Antioxidant Enzymes. Aerobic
cells are inherently equipped with natural enzymatic and
nonenzymatic antioxidant systems that prevent the accumu-
lation of ROS. The enzymatic antioxidant system is a vital
component that comprises enzymes such as superoxide dis-
mutase (SOD), glutathione peroxidase, and catalase, which
catalyses the ROS to less toxic molecules and thereby plays
a key role in preventing lipid peroxidation. The superoxide
anions, which are produced during normal cell signalling
processes, are converted to hydrogen peroxide (H
2
O
2
) and
oxygen molecules (O
2
) by SOD. On the other hand, glu-
tathione peroxidase functions in detoxifying hydroperox-
ides, including DNA and lipid hydroperoxides, into water
and alcohol molecules. This enzyme catalyses the reduction
of hydroperoxides at the expense of reduced glutathione
(GSH) to produce oxidised glutathione (GSSG) and reduced
hydroperoxide. Subsequently, the GSSG is recycled to GSH
by glutathione reductase and NADPH. In addition, catalase
detoxifies H
2
O
2
molecules, which are converted to oxygen
and water molecules. Oxidative stress in cells activates the
transcription of antioxidant enzymes through the antioxidant
response element (ARE) and the binding of members of
the Cap-N-Collar family of transcription factors, including
Nuclear Factors Nrf1 and Nrf2 [41]. The Nuclear Factor
erythrocyte derived-2 (Nrf2) plays a crucial role in the acti-
vation of over 250 genes with a common cis-acting enhancer
known as ARE. These genes function in detoxification reac-
tions that include glutathione and peroxiredoxin/thioredoxin
metabolism, the generation of NADPH via the pentose phos-
phate pathway, proteostasis, and lipid peroxidation. Under
physiologic conditions, the level of Nrf2 is low in cells due
to its constant turnover. However, during oxidative stress
caused by different stimuli, the level of Nrf2 increases and
it enters the nucleus to escalate the transcription of ARE-
containing genes [42]. A substantial amount of evidence has
suggested that several proteinopathies, including tauopathies
and synucleopathies, are associated with a reduced level of
Nrf2 activity. In AD, TAU kinase (GSK-3𝛽) participates in
the phosphorylation of tau protein in microtubules, which
results in the accumulation, aggregation, and formation of
neurofibrillary tangles that induce an abnormal production
of free radicals or ROS (Figure 1). Indeed, the increased
activity of GSK-3𝛽 impairs the appropriate response of Nrf2,
which in turn inhibits the activation of ARE associated gene
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Figure 2: Protein degradation by ubiquitin-proteasome pathway. E1, E2, and E3-ubiquitinating enzymes.
activation and reduces the level of antioxidant enzymes in
affected cells. Moreover, studies have also shown that the
level of Nfr2 is extraordinarily high in the cytoplasm of
neurons located in the hippocampus region in patients with
AD, leading to the reduced transcriptional activity of Nrf2
and a lack of ARE gene activation. Nevertheless, compelling
data from recent studies suggested that a reduction in
SOD exacerbates neuronal and vascular pathology via the
development of cerebrovascular amyloidosis, gliosis, plaque-
independent neuritic dystrophy, and increased transcription
factor Nuclear Factor kappaB activity in human amyloid
precursor protein (hAPP) transgenic mice [43]. In addition,
studies have shown that catalase-A𝛽 peptide interaction and
colocalization decreased the efficiency of catalase in offsetting
cellular damage induced by the ROS intermediate H
2
O
2
in
a human neuroblastoma cell line [44]. However, there is
no significant alteration in glutathione peroxidase enzyme
activity in autopsied brain regions of AD patients, although
increased glutathione peroxidase activity was detected in
erythrocytes [45].
2.10. Proteosomal Dysfunction. The ubiquitin-proteasome
pathway (UPP) functions in maintaining cellular integrity
through the removal of abnormally folded or aggregated
proteins. The disruption in this system in clearing unwanted
protein aggregates results in accumulations of toxic and mis-
folded proteins in neuronal cells, which is regarded as patho-
logical hallmark of AD.The survival and longevity of neurons
are determined by the effective removal of abnormal protein
trash by this pathway.The UPP is comprised of ubiquitin, the
26S proteasome, ubiquitin activating enzyme (E1), ubiquitin
conjugating enzyme (E2), ubiquitin ligating enzyme (E3), and
deubiquitinating enzymes (DUB). Ubiquitin, an 8.5 kD pro-
tein 76-amino acid chain found in all eukaryotic cells, acts as a
covalent tag bymarking themisfolded or short-lived proteins
to be degraded by UPP. Initially, ubiquitin is activated and
transferred by E1 to E2, which permits the conjugation of
the target protein with ubiquitin. This reaction is mediated
by E3 ligase enzymes; ubiquitin molecules are connected to
the initial ubiquitin, generating polyubiquitin chains. The
polyubiquitin adducts serve as a preferred substrate for
proteolysis by 26S proteasome [46]. Finally, ubiquitin protein
is recycled and reused to carry more damaged proteins by
deubiquitinating enzymes, including ubiquitin C-terminal
hydrolases (UCH-L1, UCH-L3, and UCH-L5) and ubiquitin-
specific proteases (USP7 and USP14). Once deubiquitinated,
the damaged protein will enter the 26S proteasome and
undergo proteolysis to amino acids by the 20S core particle.
Therefore, the normal function of UPP is highly crucial for
the consistent clearance of abnormal protein from the neuron
to prevent the deposition of abnormal proteins that trigger
the onset of neurodegenerative diseases [47] (Figure 2).
Recent studies have shown that the intracellular deposi-
tion of phosphorylated tau and A𝛽 protein aggregates causes
a direct impairment of UPP in AD patients. Proteosome
activity is significantly decreased in brain tissue collected
from early AD patients. The intraneural deposition of paired
helical filaments in AD causes inhibitory binding of this
protein on the proteasome and results in a 56% decrease
in proteasome activity in the gyrus of AD patients. Hence,
the inability of UPP to clear the phosphorylated tau and
paired helical filament directly induces neuronal damage in
the AD brain [48]. In addition, the activities of E1 and E2
in the cytosol of AD patients were almost undetected in
postmortem samples of cerebral cortex from AD patients
compared to normal controls. These data were further
substantiated with an adult rat fraction, in which enriched
ubiquitin enzymes were found to restore the capacity of the
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AD brain cytosolic fraction to produce conjugates. Lam et al.
reported that amutant formof ubiquitin has been observed in
the brains of AD patients but not in a normal control group.
The mutant ubiquitin is a substrate for polyubiquitination
but is resistant to disassembly by deubiquitinating enzymes,
which inhibit degradation by 26S proteasomes, resulting in
the intracellular build-up of mutant ubiquitin, leading to
AD pathology [49]. Consistent with this data, recent studies
have demonstrated the close association between hyperphos-
phorylation and ubiquitinated synaptic tau, which forms
stable oligomers with increased proteasome components,
suggesting a dysfunction in ubiquitin-proteasome system in
AD [50]. Furthermore, emerging studies have shown that
a substantial decline in proteasome activity was detected in
autopsy brain samples of AD patients, particularly in the
hippocampus and parahippocampal gyrus regions, but not
in the occipital lobe or cerebellum regions. The difference
in proteasome activity in AD brains is attributed to the
inhibition of proteasome activity in certain brain regions as
a result of posttranslational modification [51]. Although large
number of studies have shown the close association between
accumulation of hyperphosphorylated tau and dysfunctional
UPP, none of the studies have pointed out whether it is
the hyperphosphorylated tau that causes impairment of UPP
machinery or vice versa. Hence, more studies using cellular
models must be designed to identify the trigger point of
pathological event that results in abnormal neuron activity in
AD patients.
2.11. Microglial Activation. Glial cells are nonneuronal cells
that form the microarchitecture of the brain matter and
work closely with their active partners, astrocytes. Microglia
are a type of glial cells that account for 10–15% of all cells
present in brain. Essentially, microglia are widely accepted
as innate immune cells of the central nervous system and
play a significant role in defending the brain from patho-
logical insult. Microglia appear in a “resting state” in the
normal or healthy brain and under different stimuli, they
are activated to a classical (M1) or alternative (M2) state.
The activated M1 state microglia cells secrete proinflamma-
tory cytokines, such as tumour necrosis factor-𝛼 (TNF-𝛼),
interleukin-6 (IL-6), chemokines, ROS, interleukin-1𝛽 (IL-
1𝛽), and acute phase proteins, to eliminate the invading
pathogens. On the other hand, the M2 activated microglia
maintain homeostasis by downregulating the effects of
proinflammatory cytokines through the secretion of anti-
inflammatory cytokines. Intriguingly, activatedM1 microglia
cells have been demonstrated to surround amyloid plaques in
AD brain tissues and triggering proinflammatory responses
in an attempt to clear A𝛽 from the brain. Moreover, the
resulting release of cytokines, complement activation, and
phagocytosis exert detrimental effects on the surrounding
neuronal cells by disrupting synaptic plasticity, promoting
tauopathies, and suppressing the microglial clearance of A𝛽,
which leads to neuronal loss in AD [60].
Most recently, a genome-wide association study (GWAS)
has identified a novel association of the HLA-DRB4-DRB1
region (that encodes MHC-II) with the late onset of AD
[61]. In another GWAS, the CD33 gene was found to modify
microglial function in AD (though not entirely) as it plays a
role in immune responses [62]. However, the most striking
GWAS identified a variant in TREM2 (triggering receptor
expressed on myeloid cells 2) as a risk factor for the late
onset of AD [63]. TREM2, together with DAP12, plays key
role in mediating the phagocytosis of invading pathogens
and apoptotic cells and suppresses inflammatory cytokine
expression triggered by Toll-like receptor-2 (TLR-2) and
TLR-4 signalling. Although both TREM2 and DAP12 are
increased in late onset AD, the mechanism of how these
receptors regulate microglial activation is not clear [63, 64].
2.12. Neuroinflammation. Neuroinflammation is a complex
sequence of inflammatory events in nervous tissue that
are triggered in response to infection, trauma, and toxic
substances. In the past 20 years, a wealth of information
has emerged associating aging and AD with neuroinflamma-
tion (Table 1). In addition to neuronal cells, microglia and
astrocytes are major cells that are involved in inflammatory
events in the central nervous system. The initial discovery
was made byMcGeer et al., by demonstrating the presence of
reactive microglia in substantia nigral region of postmortem
brain tissue of PD patients. As a consequence of persistent
microglial activation that surrounds both A𝛽 and tau tangles,
the glial cells lose their homeostatic function and attain
a proinflammatory characteristic and intensify neuronal
damage. In the event of neuroinflammation, inflammatory
mediators, such as TNF-𝛼, IL-6, IL-1𝛽, and cyclooxygenase-
2 (COX-2), are found in serum and brain samples of AD
patients [65].
Inducible COX-2 has been found to be stimulated in
rat model neurodegenerative studies. In addition, the upreg-
ulation of COX-2 gene expression was detected in the
frontal cortex of AD patients. Inducible COX-2 synthesizes
different types of prostaglandins (PGs) (PGE
2
, PGD
2
, and
PGF2𝛼) from arachidonic acid and studies have shown that
PGs stimulate microglia via PG receptors that are found
in microglia and trigger the production of proinflamma-
tory cytokines. PGE
2
is a crucial proinflammatory marker
of the neuroinflammation process, as the PGE
2
level was
upregulated in the CSF of AD patients [66]. Caspases are
cysteine aspartic proteases that play a significant role in
neuroinflammation and cellular apoptosis. Data in support of
this idea include studies by Burguillos et al. that showed that
microglia can release various potentially neurotoxic proin-
flammatorymediators through a protein kinase C- (PKC-) 𝛿-
dependent pathway.These caspaseswere detected in activated
microglia collected from the ventral mesencephalon of PD
patients and from frontal cortex areas of patients with AD
[55]. In light of the finding that chronic inflammation is an
important histopathologic feature in AD, recent studies have
revealed that the stimulation of human primary astrocytes
or the astrocytoma cell line U373 with IFN𝛾 and TNF𝛼 or
IFN𝛾 and IL-1𝛽 triggered the production of A𝛽1–40 and
A𝛽1–42.The combination of IFN𝛾with either TNF𝛼 or IL-1𝛽
stimulated A𝛽 production mediated by 𝛽-secretase cleavage
of the immature amyloid precursor protein (APP) molecule
[67, 68]. On the other hand, Holmes et al. have demonstrated
that an increase in serum TNF-𝛼 is clearly correlated with
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Table 1: Evidence of inflammatory mediators reported in AD.
Inflammatory mediator Changesreported Human site References
Tumour necrosis factor-𝛼 (TNF-𝛼)
↑ Serum [52]
↑ Brain
↑ Brain
↑ Blood
Interleukin-6 (IL-6)
↑ Serum [53]
↑ Brain [54]
↑ Serum [55]
↑ CSF
Interleukin-1𝛽 (IL-1𝛽)
↑ Brain [56]
↑ Blood [55]
↑ CSF
Cyclooxygenase-2 (COX-2) ↑ Neurons [57]
Interleukin-2 (IL-2) ↑ Serum [55]
↑ CSF
Monocyte chemotactic protein (MCP-1) ↑ Brain [52]
↑ Blood
Caspase-8 ↑ Neurons [57]
↑ Microglia [58]
Caspase-3/7 ↑ Microglia [58]
Transforming growth factor (TGF) 𝛽1 ↑ CSF [59]
Transforming growth factor (TGF) 𝛽2 ↑ CSF [59]
the rate of cognitive decline in AD patients compared to
the low TNF-𝛼 level in the control group that showed no
cognitive decline over the same period of time. Hence, this
study further supported the hypothesis that acute episodes
of systemic inflammation, particularly, TNF-𝛼, are linked to
long-term cognitive decline in AD [68].
2.13. NeuroepigeneticModification. Theterm “epigenesis”was
first proposed by Waddington as heritable changes in gene
expression that was not originated from physical changes
in DNA sequence. Hence, neuroepigenetic alterations can
be explained as changes in neuronal DNA that switches
“on” or “off” certain genes which contributes to the onset
of pathological changes in neurodegenerative diseases, such
as Alzheimer’s disease. The two well established epigenetic
modifications that orchestrate changes in large number of
genes across multiple pathways are DNA methylation and
histone modification.
DNA methylation is an extremely conserved mecha-
nism that occurs with the transfer of a methyl group
to a single stranded DNA, particularly at the 5󸀠-C-p-G-
3󸀠 (CpG) sites. In mammalian cells, the cytosine methy-
lation (5mC) is regulated by four types of DNA methyl-
transferase (DNMT) enzymes, namely, DNMT1, DNMT2,
DNMT3A, and DNMT3B. The CpG methylation catalysed
by DNMTs interrupts the attachment of transcription factors
and allows the binding of methyl-CpG-binding domain
proteins (MBDs) that are directly associated with chromatin
compaction and gene silencing. A recent DNA methylation
study revealed that A𝛽 treated DNA samples collected from
neurons showed a significant change in DNA methylation
load besides upregulating the apoptotic and neuronal dif-
ferentiation genes. In light of this finding, it is very clear
that neuroepigeneticmodifications are triggered by upstream
mechanism of intracellular accumulation of A𝛽 that leads
to downstream changes in DNA methylation process that
regulates changes in gene expression that exacerbate the
disease process in AD [69]. Evidence in support of this
comes from Chouliaras et al. that demonstrated that the
levels of DNA methylation and DNA hydroxymethylation
(5hmc) were significantly decreased and inversely correlated
with presence of amyloid plaque load in the hippocampal
subregion of AD patients. Lately, DNA hydroxymethylation
has been described in the field of epigenetics as oxidation
of methylated cytosine by an enzyme known as ten-eleven
translocation (TET).WhereasDNAmethylation is associated
with silencing of gene, DNA hydroxymethylation results in
increased gene expression [57]. On the contrary, significant
increase in global DNA methylation was reported from
DNA sample isolated from peripheral blood mononuclear
cells of late onset of Alzheimer’s disease (LOAD) patients.
Interestingly, DNA hypermethylation levels were associated
with inheritance of APOE polymorphic 𝜀4 carriers, the
important genetic determinants of AD risk in global pop-
ulation [58]. Besides that, evidence from gene sequencing
studies has shown that decreased level of triggering receptor
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expressed on myeloid cells 2 (TREM2) enhanced the A𝛽
deposition and neuronal loss in mousemodel of AD. TREM2
is an important receptor expressed on microglia that func-
tions in regulating proinflammatory response via promoting
phagocytosis, degradation, and removal of toxic protein A𝛽
accumulation in AD brains.Mutation or aberrations that give
rise to single-nucleotide polymorphism (rs75932628) within
TREM2 are associated with disruption in the expression
of TREM2 receptor that triggers inflammatory response,
oxidative radicals, and neurotoxin production and eventually
production of A𝛽 protein [59]. According to Lue et al.,
TREM2 protein expression was remarkably correlated with
increased phosphorylated tau and proinflammatory media-
tor, caspase 3 in postmortem temporal cortical samples of
AD patients [70]. Consistent with this finding, Ozaki et al.
have reported that the increase in TREM2mRNA expression
was negatively correlated with DNAmethylation at CpG sites
in intron 1 of TREM2 region in leucocytes of AD patients
compared to that in control. Therefore, DNA methylation
status may contribute to alteration in gene expression that
exacerbated the neuroinflammation process, phosphorylated
tau formation, and apoptosis of neurons leading to AD [59].
Nevertheless, studies have shown the levels of 5mC and 5hmc
were markedly increased in human middle frontal gyrus and
middle temporal gyrus in AD patients alongside phosphory-
lated amyloid beta, tau, and ubiquitin proteins. However, the
levels of 5hmc and 5mc were significantly lower in astrocytes
and microglia compared to remarkable elevation in neurons.
Hence, it is of the utmost importance to determine the time
frame of sample collection in DNA methylation study as
the level changes during advancement of AD pathology and
this information can be used to develop biomarker for early
diagnosis of the disease and as a therapeutic approach [71].
Histone modifications, such as histone acetylation and
deacetylation, are two types of epigenetic changes that
are responsible for preserving the chromatic stability. His-
tone acetylation is regulated by two opposing enzymes,
histone acetyltransferases (HATs) and Histone deacetylases
(HDACs). HATs are responsible for addition of an acetyl
group to lysine residues at the N terminus of histone
proteins and reveal the chromatin structure allowing easy
accessibility for transcription factor binding increased gene
expression. Conversely, HDACs remove acetyl groups and
maintain closed chromatin structure with gene transcription
repression. Overwhelming studies have suggested that free
radicals and oxidative stress resulting from aging, hypoxia,
and hyperglycemia may spiral out of control resulting in
A𝛽 and NFT induced neuronal death. Recent studies have
demonstrated that hydrogen peroxide activated the his-
tone acetyltransferases p300/CAMP-response element bind-
ing protein (p300/CBP) and downregulated the HDAC3,
which might indirectly activate enzyme-dependent global
histone hyperacetylation. The histone hyperacetylation via
CBP/p300 cascade played a major role in the upregula-
tion of inflammatory mediator, NF-𝜅B, that mediates gene
expression for A𝛽 production under oxidative stress [72].
Along with this, histone hyperacetylation has been found to
activate stress-related gene pathways that could upregulate
the transcription of APP, BACE-1, and PS1 genes, therefore
causing overproduction of A𝛽 in AD [73]. In accordance
with this data, Narayan et al. have demonstrated that acetyl
histone H3 and acetyl histone H4, including total histones
H3 andH4, were remarkably increased in pyramidal neurons
from postmortem AD patients. Intriguingly, a significant
correlation was discovered between histone hyperacetylation
and compromised protein degradation pathway resulting in
build-up in ubiquitin load and cell death [74]. Similarly,
Lithner et al. have revealed that histone hyperacetylation was
observed in histone H3 at lysine 9 of postmortem neocortex
(occipital cortex) of AD patients [75]. Surprisingly, studies
conducted on animal model of AD showed significantly
decreasedH3 andH4 histone acetylation that was induced by
accumulation of A𝛽 that affected reduction in neuroligin 1, a
critical gene involved in synaptic plasticity causing memory
deficit [76]. In addition, Gjoneska et al. have reported the
decreasedH3K27 acetylation at regulatory regions of synaptic
plasticity genes in the p25 transgenic model of AD [77].
In order to counteract the decreased acetylation in histone,
HDAC inhibitors have been used to improve histone acety-
lation that in turn alleviates the detrimental effect of A𝛽
induced neurotoxic effect in mouse model of AD. A number
of HDAC inhibitors including 4-phenyl butyrate, valproic
acid, trichostatin A, and suberoylanilide hydroxamic acid
(SAHA) have been reported to increase histone acetylation in
mouse model of AD. Fonta´n-Lozano et al. have reported that
HDAC inhibitors reversed learning and consolidation deficit
via increasing H3 histone acetylation that causes modulation
of genes that are responsible formemory and learning inmice
model of AD [76]. It is quite puzzling, on the role of HDAC
inhibitors in elevating histone acetylation in human brain, as
recent studies have shown that histone acetylation is greatly
elevated in postmortem samples of AD [74]. Consistent
with this idea, the effect of HDAC inhibitor, valproate,
was tested on a randomized, double-blind study using AD
patients, and the study reported that valproate is not effective
in the management of agitation and aggression. Moreover
patients experienced significant worsened adverse reaction in
postvalproate therapy [78]. Therefore, more research should
be aimed at elucidating the role of HDAC inhibitors in
histone acetylating enzymes along with other pathways such
as inflammation, oxidative stress, and microglia activation as
more solid understanding will be gained on the molecular
changes exerted by HDAC inhibitors. Besides that, more
clinical studies should be conducted to verify the efficacy
of HDAC inhibitors as a potential therapeutic strategy
in mitigating synaptic microtubule damage and memory
impairment in AD patients.
3. Conclusion
This review summarized the current concepts on neurode-
generative pathways that may lead to a “domino” cascade of
events leading to manifestation of AD. Aging and oxidative
stress are currently recognized as key factors that cause the
pathophysiological features of these diseases. The inevitable
aging process may augment ROS formation and accumu-
lation, which activate several neurodegenerative pathways
and lead to neuronal loss. Multiple pathways have been
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recognized to cause AD, but these changes are not seen in all
cases of AD. Treatment strategies can be achieved by targeting
the specific pathways that were activated, such as halting
the deleterious neuroinflammatory pathway, improving the
clearance of aggregated protein by UPP, and augmenting the
endogenous antioxidant enzyme level.
It is extremely important to understand the intricate
details of disease mechanism, as this understanding allows
researchers and clinicians to identify the right therapeutic
approach and disease management at an early stage; late
stage of AD usually has a lower success rate of treatment.
To be diagnosed at an early stage of the disease, it is
essential to define the biomarkers that correctly indicate
the onset of the disease in patients. Disease biomarkers can
also be used to monitor the severity of the disease and
the response to prescribed drugs. Efforts to discover more
diagnostic biomarkers should be encouraged and integrated
with state-of-the-art approaches to experimental and clinical
trial designs to discover suitable treatments for these diseases.
Given the explosive amount of information on AD, we are
sure that the discovery of an ideal therapeutic drug for AD
will be achieved in the near future.
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